CJC-1295: The Long-Acting GHRH Analogue Reshaping Growth Hormone Research
CJC-1295 is a modified form of growth hormone-releasing hormone that lasts days instead of minutes. This guide explains its mechanism, what the human trials show, and how it compares to other GH-stimulating peptides.
Growth hormone releasing hormone (GHRH) is the master signal your hypothalamus sends to your pituitary to release growth hormone. In its natural form, GHRH lasts only a few minutes before being broken down. CJC-1295 is a modified version engineered to last days — and the results in clinical research have been striking.
What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH 1-29). It has been modified at four amino acid positions to resist breakdown by the enzyme dipeptidyl peptidase IV (DPP-IV), and it is conjugated to Drug Affinity Complex (DAC) technology that allows it to bind to albumin in the bloodstream.
This albumin binding is the key innovation. Natural GHRH has a half-life of about 7 minutes. Sermorelin (an earlier GHRH analogue) lasts 10-20 minutes. CJC-1295 with DAC has a half-life of 6-8 days, meaning a single injection maintains active GHRH signaling for a week.
There is also CJC-1295 without DAC (also called Mod GRF 1-29), which has a shorter half-life of 30-45 minutes and is typically used in combination with ipamorelin for a more pulsatile GH release pattern.
How Does CJC-1295 Work?
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, activating adenylyl cyclase and increasing intracellular cAMP. This triggers the release of stored growth hormone in a dose-dependent manner.
Because CJC-1295 with DAC maintains continuous GHRH receptor stimulation, it produces a sustained elevation in GH pulse amplitude rather than a single large pulse. This results in elevated IGF-1 levels that are maintained for the duration of the dosing interval.
The combination of CJC-1295 with ipamorelin is particularly powerful because it activates two different receptor systems simultaneously:
- CJC-1295 → GHRH receptor → cAMP pathway
- Ipamorelin → GHSR → calcium pathway
The dual pathway activation produces GH pulses 2-10x larger than either peptide alone.
What Do Human Clinical Trials Show?
CJC-1295 is one of the few GH-stimulating peptides with published human Phase 1/2 trial data:
Ionescu and Frohman (2006) — Journal of Clinical Endocrinology and Metabolism.
This seminal study enrolled healthy adults aged 21-61 and administered single doses of CJC-1295 ranging from 30-120 mcg/kg. Results showed:
- Mean GH levels increased 2-10 fold above baseline
- IGF-1 increased 1.5-3.0 fold above baseline
- GH elevation was maintained for 6+ days following a single injection at the highest dose
- IGF-1 remained elevated for 9-11 days
Multiple-dose study findings. With once or twice-weekly dosing, CJC-1295 maintained IGF-1 in the upper normal range for adults in their 20s-30s, even in subjects who were 40-60 years old with baseline IGF-1 in the lower range.
Body composition effects. Subjects showed statistically significant reductions in percent body fat and increases in lean body mass over 12-week treatment periods, consistent with GH/IGF-1's anabolic and lipolytic actions.
CJC-1295 vs. Sermorelin: Key Differences
| Sermorelin | CJC-1295 (DAC) | |
|---|---|---|
| Half-life | 10-20 minutes | 6-8 days |
| Dosing frequency | Daily | Weekly |
| GH pulse pattern | More physiological | More sustained |
| IGF-1 elevation | Moderate | Robust |
| Human trial data | Limited | Phase 1/2 published |
Research Dosing Protocols
CJC-1295 with DAC:
- 2 mg subcutaneous injection once or twice weekly
- Produces sustained IGF-1 elevation throughout the dosing interval
CJC-1295 without DAC (Mod GRF 1-29) + ipamorelin combination:
- 100-200 mcg CJC-1295 no DAC + 100-300 mcg ipamorelin
- Subcutaneous injection 1-3 times daily, ideally at bedtime and/or post-exercise
Safety Profile
In published human trials, CJC-1295 was well-tolerated with no serious adverse events:
- Most common: mild flushing and water retention during initial weeks
- Transient injection site reactions
- Mild headache during first 1-2 weeks of treatment
- Theoretical concern about sustained GH elevation and insulin resistance; monitoring of fasting glucose recommended with long-term use
The Bottom Line
CJC-1295 is arguably the most evidence-backed synthetic GHRH analogue, with published human clinical trial data showing robust and sustained GH/IGF-1 elevation. Its combination with ipamorelin has become a gold standard stack in peptide research for anti-aging and body composition applications. For anyone interested in GH optimization through physiologically coherent mechanisms, CJC-1295 represents the current state of the art in GHRH-based research.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.